Inclisiran Lowers LDL Cholesterol Across Glycaemic and BMI Strata, suggests study Dr Riya Dave17 Aug 2024 9:30 AM ISTResearchers have found that inclisiran significantly lowers LDL cholesterol across various glycaemic and BMI strata, with consistent efficacy and...
Inclisiran treatment in high-risk patients provides sustained reductions in LDL-cholesterol: ORION-3 Medha Baranwal19 Jan 2023 9:30 AM ISTUSA: In patients with high cardiovascular risk and elevated LDL cholesterol, twice-yearly inclisiran provided early reductions in LDL cholesterol and...
PCSK9 levels may not predict severity or recurrence of CV events after MI: Study MD Bureau1 Dec 2020 12:45 PM ISTResearchers have found in a new study that PCSK9 levels are not predictors of severity or recurrence of cardiovascular events in patients of...
Tafolecimab significantly reduces LDL-C, confirms Phase 1/2 Clinical Study Hina Zahid4 Sept 2020 9:45 AM ISTTafolecimab, an innovative PCSK9 inhibitor developed locally with good safety and tolerability profile, can significantly reduce LDL-C, find phase 1/2...
PCSK9 inhibitor Evinacumab may significantly lower LDL cholesterol in FH: NEJM Medha Baranwal21 Aug 2020 11:30 AM ISTDelhi: Evinacumab significantly lowers LDL cholesterol levels in patients with homozygous familial hypercholesterolemia receiving maximum...
PCSK9 inhibitors may improve function of coronary arteries also: JAHA study Dr. Kamal Kant Kohli30 July 2020 8:30 PM ISTResearchers at Johns Hopkins Medicine have found in a pilot study that a six-week course of a cholesterol-lowering medication improved the function of...
Alirocumab may cause scleritis with uveal effusion in susceptible patients Dr. Kamal Kant Kohli10 March 2020 1:00 PM ISTAlirocumab has been linked to scleritis with uveal effusion in patient with autoimmune diseases according to a case study. In the literature...
